Drug intelligence / Profile preview

Moisturizing Durable Barrier Cream

Development stage: Preclinical
Lead developer: 3M
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

Moisturizing Durable Barrier Cream (MDBC) is a topical cream investigated for the prophylactic management of postmastectomy irradiation skin care. It functions as a barrier cream, aiming to moisturize and protect the skin to prevent or reduce the severity of radiation-induced skin toxicity, such as moist desquamation, in patients undergoing radiotherapy. The cream was evaluated in a randomized, double-blind clinical trial (TROG 04.01) comparing its efficacy against a 10% glycerine cream.

Beyond the preview

Go deeper on Moisturizing Durable Barrier Cream.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moisturizing Durable Barrier Cream.

Explore the full profile